Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
HBM Healthcare Investments
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==The board == {| class="wikitable" |+Exhibit 18: HBM Healthcare Investments’ board of directors<ref>Source: HBM Healthcare Investments. Notes: *Board fees are made up of a fixed fees (a base fee of CHF94,000 for the chairman, CHF43,000 for the vice-chairman and CHF28,000 for the other directors, plus fees for meetings and committee attendance), plus a variable amount based on the fund’s performance (no performance-related fees in FY22). The variable fees are funded out of the performance fee received by the manager. **Appointed at June 2021 AGM. ***Shares are held mainly by Nogra Pharma Invest, in which Mario G Giuliani has a beneficial interest.</ref> |'''Board member''' |'''Date of appointment''' |'''Remuneration in FY22 (CHF)*''' |'''Shareholdings at end-FY22''' |- |Hans Peter Hasler (chairman) |2009 |140,000 |12,841 (+5,131) |- | Dr Rudolf Lanz |2003 |70,000 |2,791 (+156) |- |Mario G Giuliani |2012 |51,367 | 1,104,132*** (+2,643) |- |Dr Stella X Xu |2020 |50,000 | 608 (+608) |- |Dr Elaine V Jones** |2021 | 50,000 |0 (0) |} Following the retirement of three long-serving board members, Prof Dr Heinz E Riesenhuber, Dr Eduard E Holdener and Robert A Ingram, at the June 2021 AGM, HBMN now has five directors – three men and two women – with an average tenure of nine years. All of the board members have relevant scientific and/or business expertise, and each director has specific responsibilities regarding the monitoring of HBMN’s portfolio and the wider market environment. The chairman, Hans Peter Hasler, covers regulatory (FDA) approval and sector and marketing strategies; Mr Giuliani monitors management, production and audit; Dr Lanz (a lawyer and corporate financier) also covers audit, as well as finance and M&A transactions; Dr Xu assesses research and development; and Dr Jones brings sector and venture capital expertise.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)